A new concept for the treatment of cancer
Crystal structure of human MTH1 in complex with a key inhibitor.
Source: Stockholm University, Prof. Pal Stenmark.
A team of researchers from five Swedish universities has identified a new way to treat cancer. They present their concept in the journal „Nature“. It is based on inhibiting a specific enzyme called MTH1. Cancer cells, unlike normal cells, need MTH1 to survive. Without this enzyme, oxidized nucleotides are incorporated into DNA, resulting in lethal DNA double-strand breaks in the cancer cells. The research group at Stockholm University has determined the structure of MTH1 based on diffraction measurements at HZB´s MX-beamline at BESSY II. These detailed structural studies are important for the development of efficient inhibitors targeting MTH1.
In recent decades, the development of new anticancer agents focused on targeting specific genetic defects in cancer cells. These often are effective initially, but later cause trouble due to emerging rapid resistance. In the current study, the researchers present a general enzymatic activity that all cancers tested rely on and that seems to be independent of the genetic changes found in specific cancers. The research team shows that all the investigated cancer tumours need the MTH1 enzyme to survive. In this respect, cancer cells differ from normal cells, which do not need this enzyme.
“The concept is built on the fact that cancer cells have an altered metabolism, resulting in oxidation of nucleotide building blocks,” says Thomas Helleday, professor at Karolinska Institutet, who leads the study: "MTH1 repairs the oxidized building blocks, preventing the oxidative stress from being incorporated into DNA and becoming DNA damage. This allows replication in cancer cells so they can divide and multiply. With an MTH1 inhibitor, the enzyme is blocked and damaged nucleotides enter DNA, causing damage and killing cancer cells."
Normal cells do not need MTH1 as they have regulated metabolism preventing damage of nucleotide building blocks. Finding a general enzymatic activity required only for cancer cells to survive opens up a whole new way of treating cancer.
Original publication:
“MTH1 inhibition kills cancer by preventing sanitation of the dNTP pool”, Helge Gad, Tobias Koolmeister, Ann-Sofie Jemth et al., Nature, online 2 April 2014, doi: 10.1038/nature13181. http://dx.doi.org/10.1038/nature13181.
“Stereospecific targeting of MTH1 by (S)-crizotinib as anticancer strategy”, Kilian V. M. Huber, Eidarus Salah, Branka Radic et al., Nature, online 2 April 2014, doi: 10.1038/nature13194. http://dx.doi.org/10.1038/nature13194
- BESSY II: Insight into ultrafast spin processes with femtoslicingAn international team has succeeded at BESSY II for the first time to elucidate how ultrafast spin-polarised current pulses can be characterised by measuring the ultrafast demagnetisation in a magnetic layer system within the first hundreds of femtoseconds. The findings are useful for the development of spintronic devices that enable faster and more energy-efficient information processing and storage. The collaboration involved teams from the University of Strasbourg, HZB, Uppsala University and several other universities.
- Battery research: visualisation of aging processes operandoLithium button cells with electrodes made of nickel-manganese-cobalt oxides (NMC) are very powerful. Unfortunately, their capacity decreases over time. Now, for the first time, a team has used a non-destructive method to observe how the elemental composition of the individual layers in a button cell changes during charging cycles. The study, now published in the journal Small, involved teams from the Physikalisch-Technische Bundesanstalt (PTB), the University of Münster, researchers from the SyncLab research group at HZB and the BLiX laboratory at the Technical University of Berlin. Measurements were carried out in the BLiX laboratory and at the BESSY II synchrotron radiation source.
- New instrument at BESSY II: The OÆSE endstation in EMILA new instrument is now available at BESSY II for investigating catalyst materials, battery electrodes and other energy devices under operating conditions: the Operando Absorption and Emission Spectroscopy on EMIL (OÆSE) endstation in the Energy Materials In-situ Laboratory Berlin (EMIL). A team led by Raul Garcia-Diez and Marcus Bär showcases the instrument’s capabilities via a proof-of-concept study on electrodeposited copper.